Addex Therapeutics Management
Management criteria checks 2/4
Addex Therapeutics' CEO is Tim Dyer, appointed in Jan 2002, has a tenure of 22.83 years. directly owns 9.41% of the company’s shares, worth €562.17K. The average tenure of the management team and the board of directors is 7.7 years and 9.4 years respectively.
Key information
Tim Dyer
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 22.8yrs |
| CEO ownership | 9.4% |
| Management average tenure | 7.7yrs |
| Board average tenure | 9.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CHF 11m |
| Jun 30 2024 | n/a | n/a | -CHF 12m |
| Mar 31 2024 | n/a | n/a | -CHF 11m |
| Dec 31 2023 | n/a | n/a | -CHF 11m |
| Sep 30 2023 | n/a | n/a | -CHF 7m |
| Jun 30 2023 | n/a | n/a | -CHF 9m |
| Mar 31 2023 | n/a | n/a | -CHF 15m |
| Dec 31 2022 | n/a | n/a | -CHF 21m |
| Sep 30 2022 | n/a | n/a | -CHF 22m |
| Jun 30 2022 | n/a | n/a | -CHF 21m |
| Mar 31 2022 | n/a | n/a | -CHF 19m |
| Dec 31 2021 | n/a | n/a | -CHF 15m |
| Sep 30 2021 | n/a | n/a | -CHF 13m |
| Jun 30 2021 | n/a | n/a | -CHF 13m |
| Mar 31 2021 | n/a | n/a | -CHF 11m |
| Dec 31 2020 | CHF 917k | CHF 454k | -CHF 13m |
| Sep 30 2020 | n/a | n/a | -CHF 14m |
| Jun 30 2020 | n/a | n/a | -CHF 15m |
| Mar 31 2020 | n/a | n/a | -CHF 16m |
| Dec 31 2019 | CHF 709k | CHF 429k | -CHF 15m |
| Sep 30 2019 | n/a | n/a | -CHF 13m |
| Jun 30 2019 | n/a | n/a | -CHF 12m |
| Mar 31 2019 | n/a | n/a | -CHF 6m |
| Dec 31 2018 | CHF 2m | n/a | -CHF 2m |
Compensation vs Market: Insufficient data to establish whether Tim's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
CEO
Tim Dyer (56 yo)
22.8yrs
Tenure
Mr. Timothy Mark Dyer, also known as Tim, has been Chief Executive Officer at Addex Therapeutics Ltd. since June 1, 2013. Mr. Dyer co-founded Addex Therapeutics Ltd.(also known as Addex Pharmaceuticals Lt...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 22.8yrs | no data | 9.41% € 562.2k | |
| Chief Medical Officer & Director | 8yrs | no data | no data | |
| Head of Finance | 7.4yrs | no data | no data | |
| Head of Translational Science | 3.3yrs | no data | no data |
7.7yrs
Average Tenure
56.5yo
Average Age
Experienced Management: APE1's management team is seasoned and experienced (7.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | no data | 9.41% € 562.2k | |
| Chief Medical Officer & Director | 7.8yrs | no data | no data | |
| Independent Director | 6.4yrs | CHF 41.29k | no data | |
| Non-Executive Director | 9.4yrs | CHF 89.65k | 1.39% € 83.0k | |
| Independent Chairman of the Board | 15.6yrs | CHF 155.75k | 2.55% € 152.4k |
9.4yrs
Average Tenure
67yo
Average Age
Experienced Board: APE1's board of directors are considered experienced (9.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/24 11:52 |
| End of Day Share Price | 2024/08/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Addex Therapeutics Ltd is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Bob Pooler | Bank am Bellevue |
| Silvia Schanz | Bank Vontobel AG |